timothy sykes logo
SLS Stock Climbs As Analyst Upside Targets REGAL Trial Thumbnail
G Google News

SLS Stock Climbs As Analyst Upside Targets REGAL Trial

JACK KELLOGG•UPDATED JUL. 17, 2026, 11:32 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

SELLAS Life Sciences Group Inc. stocks have been trading up by 10.72 percent amid heightened optimism around its latest oncology developments.

Key Takeaways

  • Alliance Global raised its price target on Sellas Life Sciences to $25 from $10, tied to the Phase 3 REGAL trial of Galinpepimut-S in acute myeloid leukemia.
  • The firm views the slower pace of required deaths in REGAL as a constructive sign that patients may be living longer versus best available therapy.
  • Shares of Sellas Life Sciences jumped 16.8% to $14.47 in early trading on 2026/06/29 with no fresh fundamental news.
  • The next day, Sellas Life Sciences dropped 8.9% to $14.08, again on a quiet news tape, highlighting sharp trading swings.

Candlestick Chart

Live Update At 11:32:08 EDT: On Friday, July 17, 2026 SELLAS Life Sciences Group Inc. stock [NASDAQ: SLS] is trending up by 10.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SELLAS Life Sciences Group Inc. is trading like a classic clinical-stage biotech: heavy on cash, light on revenue, and driven by trial headlines. The recent daily chart shows SLS grinding higher from $8.53 on 2026/06/22 to around $13.01 on 2026/07/17, with multiple spikes above $15 along the way. That is a strong multi-week uptrend, but also a choppy one, with wide intraday ranges.

On the intraday tape, SLS opened near $11.65 and pushed to a high of $13.543 before settling around $13.01. That intraday ramp shows real buying pressure, with dips repeatedly getting scooped. For active traders, that kind of action usually signals momentum funds and day traders piling in.

More Breaking News

Financially, SLS is still burning cash. The latest quarter shows about -$8.4M in net loss and operating cash outflow of roughly -$8.8M, but it also ended with about $107.1M in cash and short-term investments. With just 15 employees and minimal debt, the balance sheet is built to support clinical work, not profitability. Ratios like a current ratio above 17 and almost no long-term debt tell traders that near-term dilution risk is manageable, even as losses continue.

Why Traders Are Watching SLS Now

Traders are glued to SELLAS Life Sciences Group Inc. because the story has finally moved from “hope” to a concrete late-stage catalyst. Alliance Global just hiked its SLS price target to $25 from $10 and kept its Buy rating. That is not a small nudge. It is a full re-rate, and the firm tied the call directly to what it sees in the Phase 3 REGAL trial of Galinpepimut-S for second-remission acute myeloid leukemia.

The key detail for traders: REGAL is taking longer than expected to hit the required number of deaths needed for top-line data. Alliance Global is reading that as good news, implying patients on the SLS regimen may be living longer than those on best available therapy. In biotech, time-to-event delays like this often spark serious speculation, because they hint that the experimental drug might be helping.

Layer that thesis on top of SLS price action. On 2026/06/29, shares ripped 16.8% to $14.47 in early trading with no new fundamental news. The following day, they dropped 8.9% to $14.08, again without any fresh catalyst. That back-to-back whipsaw tells traders exactly what this is: a sentiment-driven battleground around a binary trial.

For short-term setups, SLS has the ingredients momentum traders hunt—clear news anchor (REGAL), analyst validation, and a tape that punishes late entries. For longer-term, catalyst-focused traders, the Alliance Global call underscoring possible survival benefit puts SLS squarely on the watchlist.

Conclusion

SLS is sitting at the intersection of a bullish analyst call, a pivotal cancer trial, and a chart full of volatility. The uptrend from the high single digits into the low to mid-teens shows that traders are already pricing in a better outcome for Galinpepimut-S and the REGAL study. At the same time, the violent 16.8% pop followed by an 8.9% drop on no fresh news reminds everyone how unforgiving clinical-stage biotech trading can be.

The fundamentals of SELLAS Life Sciences Group Inc. remain classic “pre-revenue biotech”: negative earnings, significant cash burn, but a sizable cash pile of roughly $107.1M and minimal debt. That gives SLS runway to push REGAL forward without immediately scrambling for capital, which matters for anyone tracking dilution risk around catalysts.

For active traders, SLS is not about steady cash flows; it is about timing and discipline around the REGAL readout and any interim updates. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your preparation and your discipline.” As millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.”. Applying that mindset to SLS means mapping key price levels, respecting the volatility, and treating the Alliance Global upgrade and REGAL timelines as key reference points—strictly for educational and research purposes, not as a signal to buy or sell.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”